Search

Your search keyword '"Rieth, Andreas J."' showing total 26 results
Start Over Author "Rieth, Andreas J."
26 results on '"Rieth, Andreas J."'

4. Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction

Author

Patel, Ravi B., primary, Silvestry, Frank E., additional, Komtebedde, Jan, additional, Solomon, Scott D., additional, Hasenfuß, Gerd, additional, Litwin, Sheldon E., additional, Borlaug, Barry A., additional, Price, Matthew J., additional, Kawash, Rami, additional, Hummel, Scott L., additional, Cutlip, Donald E., additional, Leon, Martin B., additional, van Veldhuisen, Dirk J., additional, Rieth, Andreas J., additional, McKenzie, Scott, additional, Bugger, Heiko, additional, Mazurek, Jeremy A., additional, Kapadia, Samir R., additional, Vanderheyden, Marc, additional, Ky, Bonnie, additional, and Shah, Sanjiv J., additional

Published
2024
Full Text
View/download PDF

7. Echocardiographic pressure–strain loop‐derived stroke work of the right ventricle: validation against the gold standard

Author

Richter, Manuel J., primary, Douschan, Philipp, additional, Fortuni, Federico, additional, Gall, Henning, additional, Ghofrani, Hossein A., additional, Keranov, Stanislav, additional, Kremer, Nils, additional, Kriechbaum, Steffen D., additional, Rako, Zvonimir A., additional, Rieth, Andreas J., additional, da Rocha, Bruno Brito, additional, Seeger, Werner, additional, Zedler, Daniel, additional, Yildiz, Selin, additional, Yogeswaran, Athiththan, additional, and Tello, Khodr, additional

Published
2023
Full Text
View/download PDF

8. Exercise MR-proANP unmasks latent right heart failure in CTEPH

Author

Kriechbaum, Steffen D., primary, Birmes, Judith, additional, Wiedenroth, Christoph B., additional, Adameit, Miriam S.D., additional, Gruen, Dimitri, additional, Vietheer, J., additional, Richter, Manuel J., additional, Guth, Stefan, additional, Roller, Fritz C., additional, Rademann, Matthias, additional, Fischer-Rasokat, Ulrich, additional, Rolf, Andreas, additional, Liebetrau, Christoph, additional, Hamm, Christian W., additional, Keller, Till, additional, and Rieth, Andreas J., additional

Published
2022
Full Text
View/download PDF

9. Hemodynamic markers of pulmonary vasculopathy for prediction of early right heart failure and mortality after heart transplantation

Author

Rieth, Andreas J., primary, Rivinius, Rasmus, additional, Lühring, Tom, additional, Grün, Dimitri, additional, Keller, Till, additional, Grinninger, Carola, additional, Schüttler, Dominik, additional, Bara, Christoph L., additional, Helmschrott, Matthias, additional, Frey, Norbert, additional, Sandhaus, Tim, additional, Schulze, Christian, additional, Kriechbaum, Steffen, additional, Vietheer, Julia, additional, Sindermann, Jürgen, additional, Welp, Henryk, additional, Lichtenberg, Artur, additional, Choi, Yeong-Hoon, additional, Richter, Manfred, additional, Tello, Khodr, additional, Richter, Manuel J., additional, Hamm, Christian W., additional, and Boeken, Udo, additional

Published
2022
Full Text
View/download PDF

10. Right ventricular–pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism

Author

Douschan, Philipp, primary, Tello, Khodr, additional, Rieth, Andreas J., additional, Wiedenroth, Christoph B., additional, Sassmann, Teresa, additional, Kovacs, Gabor, additional, Ghofrani, Hossein A., additional, Seeger, Werner, additional, Richter, Manuel, additional, and Guth, Stefan, additional

Published
2022
Full Text
View/download PDF

11. Implantation mechanischer Unterstützungssysteme und Herztransplantation bei Patienten mit terminaler Herzinsuffizienz

Author

Schulze, P. Christian, primary, Barten, Markus J., additional, Boeken, Udo, additional, Färber, Gloria, additional, Hagl, Christian M., additional, Jung, Christian, additional, Leistner, David, additional, Potapov, Evgenij, additional, Bauersachs, Johann, additional, Raake, Philip, additional, Reiss, Nils, additional, Saeed, Diyar, additional, Schibilsky, David, additional, Störk, Stefan, additional, Veltmann, Christian, additional, Rieth, Andreas J., additional, and Gummert, Jan, additional

Published
2022
Full Text
View/download PDF

12. Hemodynamic markers of pulmonary vasculopathy for prediction of early right heart failure and mortality after heart transplantation.

Author

Rieth, Andreas J., Rivinius, Rasmus, Lühring, Tom, Grün, Dimitri, Keller, Till, Grinninger, Carola, Schüttler, Dominik, Bara, Christoph L., Helmschrott, Matthias, Frey, Norbert, Sandhaus, Tim, Schulze, Christian, Kriechbaum, Steffen, Vietheer, Julia, Sindermann, Jürgen, Welp, Henryk, Lichtenberg, Artur, Choi, Yeong-Hoon, Richter, Manfred, and Tello, Khodr

Subjects
*HEART transplantation, *HEART failure, *HEMODYNAMICS, *DISEASE risk factors, MORTALITY risk factors
Abstract

Elevated pulmonary vascular resistance (PVR) is broadly accepted as an imminent risk factor for mortality after heart transplantation (HTx). However, no current HTx recipient risk score includes PVR or other hemodynamic parameters. This study examined the utility of various hemodynamic parameters for risk stratification in a contemporary HTx population. Patients from seven German HTx centers undergoing HTx between 2011 and 2015 were included retrospectively. Established risk factors and complete hemodynamic datasets before HTx were analyzed. Outcome measures were overall all-cause mortality, 12-month mortality, and right heart failure (RHF) after HTx. The final analysis included 333 patients (28% female) with a median age of 54 (IQR 46-60) years. The median mean pulmonary artery pressure was 30 (IQR 23-38) mm Hg, transpulmonary gradient 8 (IQR 5-10) mm Hg, and PVR 2.1 (IQR 1.5-2.9) Wood units. Overall mortality was 35.7%, 12-month mortality was 23.7%, and the incidence of early RHF was 22.8%, which was significantly associated with overall mortality (log-rank HR 4.11, 95% CI 2.47-6.84; log-rank p <.0001). Pulmonary arterial elastance (Ea) was associated with overall mortality (HR 1.74, 95% CI 1.25-2.30; p <.001) independent of other non-hemodynamic risk factors. Ea values below a calculated cutoff represented a significantly reduced mortality risk (HR 0.38, 95% CI 0.19-0.76; p <.0001). PVR with the established cutoff of 3.0 WU was not significant. Ea was also significantly associated with 12-month mortality and RHF. Ea showed a strong impact on post-transplant mortality and RHF and should become part of the routine hemodynamic evaluation in HTx candidates. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension

Author

Rieth, Andreas J., primary, Grün, Dimitri, additional, Zarogiannis, Georgios, additional, Kriechbaum, Steffen D., additional, Wolter, Sebastian, additional, Richter, Manuel J., additional, Tello, Khodr, additional, Krüger, Ulrich, additional, Mitrovic, Veselin, additional, Rosenkranz, Stephan, additional, Hamm, Christian W., additional, and Keller, Till, additional

Published
2022
Full Text
View/download PDF

14. Herzinsuffizienzprotektion bei Patienten mit Diabetes mellitus Typ 2 durch SGLT2-Inhibitoren – Evidenzlage und mögliche Mechanismen

Author

Rieth, Andreas J., Hamm, Christian W., Wanner, Christoph, Mitrovic, Veselin, and Keller, Till

Subjects
Heart Failure, Übersichten, Kardioprotektiver Effekt, Empagliflozin, Cardioprotective effect, Blood Pressure, Kardiorenale Interaktion, Dapagliflozin, Diabetes Mellitus, Type 2, Cardiorenal interaction, Humans, Hypoglycemic Agents, Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors
Abstract

Renal sodium-glucose cotransporter‑2 (SGLT2) inhibitors seem to have a cardioprotective effect beyond the antidiabetic effect. The underlying mechanisms are unclear.Selective search in PubMed with a focus on heart failure endpoints and possible mechanisms of action.During treatment with three of the substances analyzed, there were fewer hospitalizations for heart failure compared with placebo; however, the numbers needed to treat within the primary analyses were relatively high (72-117). We found that loss of weight and lowering of blood pressure were more pronounced during treatment with verum than with placebo and an association of the preventive effect with more severely impaired renal function.The SGLT2 inhibitors show a moderate heart failure protective effect in diabetic patients. It is likely that a nephroprotective effect with modulation of the cardiorenal interaction is an important part of the mechanism of action but this must be substantiated in further investigations.HINTERGRUND: Hemmstoffe des renalen Natrium-Glukose-Kotransporters 2 („sodium glucose-linked transporter 2“; SGLT2i) scheinen außer der antidiabetischen auch eine kardioprotektive Wirkung zu besitzen; deren Mechanismus ist jedoch unklar.Selektive Literaturrecherche in PubMed (Fokus Herzinsuffizienz und Wirkmechanismen).Unter Therapie mit 3 der untersuchten Substanzen kam es im Vergleich mit Placebo zu weniger herzinsuffizienzbedingten Krankenhausaufenthalten, allerdings mit einer relativ hohen Anzahl von Behandlungen pro verhindertes Ereignis (72–117). Außer einer stärkeren Gewichtsabnahme und Blutdrucksenkung unter dem Verum gegenüber Placebo fiel eine Zunahme des kardioprotektiven Effekts bei stärker eingeschränkter Nierenfunktion auf.Ein moderater herzinsuffizienzpräventiver Effekt von Hemmstoffen des renalen SGLT2 kann bei Diabetikern als gesichert gelten. Ein wesentlicher Wirkmechanismus beruht wahrscheinlich auf einem nephroprotektiven Effekt mit Modulation der kardiorenalen Interaktion, was jedoch weiterer Abklärung bedarf.

Published
2020

15. Application and Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio in Patients with Ischemic and Non-Ischemic Cardiomyopathy

Author

Keranov, Stanislav, primary, Haen, Saskia, additional, Vietheer, Julia, additional, Rutsatz, Wiebke, additional, Wolter, Jan-Sebastian, additional, Kriechbaum, Steffen D., additional, von Jeinsen, Beatrice, additional, Bauer, Pascal, additional, Tello, Khodr, additional, Richter, Manuel, additional, Dörr, Oliver, additional, Rieth, Andreas J., additional, Nef, Holger, additional, Hamm, Christian W., additional, Liebetrau, Christoph, additional, Rolf, Andreas, additional, and Keller, Till, additional

Published
2021
Full Text
View/download PDF

16. Exercise Hemodynamic Profiling Is Associated With Outcome in Patients Undergoing Percutaneous Mitral Valve Repair

Author

Rieth, Andreas J., primary, Kriechbaum, Steffen D., additional, Richter, Manuel J., additional, Wenninger, Elena, additional, Fischer-Rasokat, Ulrich, additional, Tello, Khodr, additional, Gall, Henning, additional, Ghofrani, Hossein A., additional, Guth, Stefan, additional, Wiedenroth, Christoph B., additional, Mitrovic, Veselin, additional, Hamm, Christian W., additional, Liebetrau, Christoph, additional, and Walther, Claudia, additional

Published
2021
Full Text
View/download PDF

17. Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart

Author

Rieth, Andreas J., primary, Richter, Manuel J., additional, Tello, Khodr, additional, Gall, Henning, additional, Ghofrani, Hossein A., additional, Guth, Stefan, additional, Wiedenroth, Christoph B., additional, Seeger, Werner, additional, Kriechbaum, Steffen D., additional, Mitrovic, Veselin, additional, Schulze, P. Christian, additional, and Hamm, Christian W., additional

Published
2021
Full Text
View/download PDF

19. Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension

Author

Kriechbaum, Steffen D., primary, Wiedenroth, Christoph B., additional, Peters, Karina, additional, Barde, Marta A., additional, Ajnwojner, Ruth, additional, Wolter, Jan-Sebastian, additional, Haas, Moritz, additional, Roller, Fritz C., additional, Guth, Stefan, additional, Rieth, Andreas J., additional, Rolf, Andreas, additional, Hamm, Christian W., additional, Mayer, Eckhard, additional, Keller, Till, additional, and Liebetrau, Christoph, additional

Published
2020
Full Text
View/download PDF

20. Exercise right heart catheterization before and after balloon pulmonary angioplasty in inoperable patients with chronic thromboembolic pulmonary hypertension

Author

Wiedenroth, Christoph B., primary, Rieth, Andreas J., additional, Kriechbaum, Steffen, additional, Ghofrani, H.‐Ardeschir, additional, Breithecker, Andreas, additional, Haas, Moritz, additional, Roller, Fritz, additional, Richter, Manuel J., additional, Lankeit, Mareike, additional, Mielzarek, Lisa, additional, Rolf, Andreas, additional, Hamm, Christian W., additional, Mayer, Eckhard, additional, Guth, Stefan, additional, and Liebetrau, Christoph, additional

Published
2020
Full Text
View/download PDF

21. Implantation mechanischer Unterstützungssysteme und Herztransplantation bei Patienten mit terminaler Herzinsuffizienz

Author

Schulze, P. Christian, Barten, Markus J., Boeken, Udo, Färber, Gloria, Hagl, Christian M., Jung, Christian, Leistner, David, Potapov, Evgenij, Bauersachs, Johann, Raake, Philip, Reiss, Nils, Saeed, Diyar, Schibilsky, David, Störk, Stefan, Veltmann, Christian, Rieth, Andreas J., and Gummert, Jan

Abstract

Die Behandlung von Patienten mit fortgeschrittener Herzinsuffizienz erfordert eine interdisziplinäre Betreuung in einem qualifizierten Herzinsuffizienzteam, insbesondere im Vorfeld und in der Nachbetreuung der Versorgung mit einem mechanischen Kreislaufunterstützungssystem (MCS) und einer Herztransplantation (HTx). Grundvoraussetzung ist die frühzeitige spezialisierte Evaluation symptomatischer Patienten auch unter optimierter Herzinsuffizienzbehandlung. Die Diagnostik und Therapie ist zunächst auf eine Prognoseverbesserung ausgerichtet. Liegen die Voraussetzungen für eine MCS- oder HTx-Therapie vor, so sind mögliche Kontraindikationen und Probleme zu evaluieren, um eine optimale Nutzen-Risiko-Relation für die genannten aufwendigen Therapien mit begrenzten Ressourcen zu erzielen. Die optimale Therapie besteht bei entsprechenden Voraussetzungen nach wie vor in der HTx, sodass diese bei allen potenziellen Patienten angestrebt werden sollte. Dabei darf das optimale, individuelle Transplantationsfenster nicht verpasst werden. Die Versorgung mit einem MCS-System ist eine mit sehr guten Ergebnissen durchgeführte Therapie für Patienten mit Ausschlusskriterien für eine HTx oder mit einer hämodynamischen Instabilität, die eine längere Wartezeit auf ein Spenderorgan verhindert. Das kurz- und mittelfristige Überleben ist bei sorgfältiger Indikationsstellung mittlerweile vergleichbar mit dem nach HTx. Entscheidend ist die rechtzeitige Implantation vor dem Auftreten von manifesten Endorganschäden. Für die optimierte Umsetzung erweiterter Therapien bedarf es professioneller Strukturen, die eine effektive interdisziplinäre Kooperation unterschiedlicher Sektoren der Gesundheitsversorgung ermöglichen.

Published
2022
Full Text
View/download PDF

23. Development of renal function during staged balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension

Author

Kriechbaum, Steffen D., primary, Wiedenroth, Christoph B., additional, Hesse, Maura L., additional, Ajnwojner, Ruth, additional, Keller, Till, additional, Sebastian Wolter, Jan, additional, Haas, Moritz, additional, Roller, Fritz C., additional, Breithecker, Andreas, additional, Rieth, Andreas J., additional, Guth, Stefan, additional, Rolf, Andreas, additional, Hamm, Christian W., additional, Mayer, Eckhard, additional, and Liebetrau, Christoph, additional

Published
2019
Full Text
View/download PDF

24. Dynamics of high-sensitivity cardiac troponin T during therapy with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

Author

Kriechbaum, Steffen D., primary, Wiedenroth, Christoph B., additional, Keller, Till, additional, Wolter, Jan Sebastian, additional, Ajnwojner, Ruth, additional, Peters, Karina, additional, Haas, Moritz A., additional, Roller, Fritz C., additional, Breithecker, Andreas, additional, Rieth, Andreas J., additional, Guth, Stefan, additional, Rolf, Andreas, additional, Bandorski, Dirk, additional, Hamm, Christian W., additional, Mayer, Eckhard, additional, and Liebetrau, Christoph, additional

Published
2018
Full Text
View/download PDF

26. [Implantation of mechanical circulatory support systems and heart transplantation in patients with end-stage heart failure : Consensus paper of the DGK, DGTHG].

Author

Schulze PC, Barten MJ, Boeken U, Färber G, Hagl CM, Jung C, Leistner D, Potapov E, Bauersachs J, Raake P, Reiss N, Saeed D, Schibilsky D, Störk S, Veltmann C, Rieth AJ, and Gummert J

Subjects
Consensus, Humans, Retrospective Studies, Treatment Outcome, Heart Failure diagnosis, Heart Failure surgery, Heart Transplantation, Heart-Assist Devices adverse effects
Abstract

The treatment of patients with advanced heart failure requires interdisciplinary care in a qualified heart failure team, especially prior to and in the follow-up of mechanical circulatory support (MCS) implantation and heart transplantation (HTx). The basic prerequisite is the early specialized evaluation of symptomatic patients even under optimized heart failure treatment. Diagnostics and treatment are initially aimed at improving the prognosis. If the prerequisites for MCS or HTx treatment are present, possible contraindications and problems have to be evaluated in order to achieve an optimal risk-benefit ratio for the abovementioned complex treatments with limited resources. The optimal treatment is still HTx if the conditions are right, so this should be sought in all potential patients. At the same time, the optimal individual transplantation window should not be missed. The provision of a MCS system is a treatment performed with very good results for patients with exclusion criteria for HTx or with hemodynamic instability that prevents a longer waiting time for a donor organ. Short-term and medium-term survival is now comparable to HTx when carefully indicated. Timely implantation before the onset of manifest end-organ damage is crucial. Optimized implementation of advanced treatment requires professional structures that enable effective interdisciplinary cooperation between different sectors of health care., (© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results